What changed: Childhood lung and airway tumours (pleuropulmonary blastoma, tracheobronchial tumours)
Every dated change on the records linked to Childhood lung and airway tumours (pleuropulmonary blastoma, tracheobronchial tumours), newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
September 2026 · 1
2018 · 2
- 2018GuidelineChildhood lung and airway tumours (pleuropulmonary blastoma, tracheobronchial tumours)Guideline DICER1 surveillance consensus (Clinical Cancer Research 2018): DICER1 carriers
Surveillance per international consensus: chest imaging in infancy and early childhood, abdominal ultrasound, thyroid ultrasound, and awareness of ovarian and other syndrome tumours.
- 2018MilestoneGermline (hereditary) testingInternational DICER1 surveillance consensus published
A milestone in how this cancer is treated.
2015 · 2
- 2015GuidelineChildhood lung and airway tumours (pleuropulmonary blastoma, tracheobronchial tumours)Guideline International PPB/DICER1 Registry recommendations (Cancer 2015): Type II or III pleuropulmonary blastoma
Neoadjuvant or adjuvant multi-agent chemotherapy (ifosfamide, vincristine, dactinomycin, doxorubicin) with complete resection; radiotherapy for unresectable residual disease.
- 2015MilestoneChildhood lung and airway tumours (pleuropulmonary blastoma, tracheobronchial tumours)Registry defines types I to III and treatment recommendations
Messinger and colleagues (Cancer 2015) report outcomes by type.